VPS51 inhibitors are a class of chemical compounds specifically designed to target and inhibit the VPS51 protein, which is a component of the Golgi-associated retrograde protein (GARP) complex. The VPS51 protein plays a crucial role in the intracellular trafficking system, particularly in the retrograde transport of vesicles from endosomes back to the trans-Golgi network. This transport system is essential for maintaining cellular homeostasis and ensuring that proteins and lipids are correctly sorted and delivered to their intended destinations within the cell. VPS51, as part of the GARP complex, interacts with other proteins such as VPS52, VPS53, and VPS54 to facilitate the tethering of vesicles to the Golgi, which is a key step in the retrograde transport pathway. Inhibitors of VPS51 are designed to disrupt this interaction, thereby impairing the function of the GARP complex and the overall retrograde transport process.
The development of VPS51 inhibitors involves a detailed understanding of the protein's structure and its interactions within the GARP complex. Researchers use techniques like X-ray crystallography, cryo-electron microscopy, and molecular docking to elucidate the binding sites and interaction domains of VPS51. This structural information is crucial for designing small molecules that can effectively bind to VPS51 and inhibit its function. High-throughput screening of chemical libraries is often employed to identify lead compounds with inhibitory activity against VPS51. These lead compounds are then further optimized through structure-activity relationship (SAR) studies, where chemical modifications are made to improve binding affinity, selectivity, and stability. Factors such as solubility, lipophilicity, and metabolic stability are also taken into consideration to ensure that the inhibitors are effective under physiological conditions. By inhibiting VPS51, researchers can explore the broader implications of disrupting the GARP complex and retrograde transport, offering insights into the fundamental processes of intracellular trafficking and protein sorting.
Items 11 to 20 of 20 total
展示:
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A可抑制ADP-核糖基化因子(ARF),后者是一种小GTP酶,对于高尔基体囊泡的形成至关重要。通过抑制ARF,Brefeldin A可间接抑制VPS51,破坏其参与的囊泡运输过程。 | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $62.00 $260.00 | 21 | |
抗真菌,可能间接影响真菌代谢途径,影响 Olr1513。 | ||||||
Tyrphostin AG 879 | 148741-30-4 | sc-3557 sc-3557A | 5 mg 25 mg | $83.00 $328.00 | 4 | |
酪氨酸激酶抑制剂AG 879可抑制酪氨酸激酶活性,从而破坏囊泡形成和运输所需的信号通路。由于VPS51是囊泡运输的组成部分,因此其功能可能会因这些信号通路的崩溃而受到抑制。 | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
血管紧张素 II 受体阻滞剂可能会间接调节细胞信号通路,影响 Olr1513。 | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $273.00 | 6 | |
SecinH3是一种细胞丝蛋白抑制剂,它参与激活ARF GTP酶,是囊泡形成所必需的。由于囊泡运输受阻,细胞丝蛋白的抑制会导致VPS51的功能抑制。 | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $82.00 $291.00 | 3 | |
Exo1是囊泡运输复合体的抑制剂,囊泡运输复合体是运输囊泡与细胞膜结合所必需的。抑制囊泡运输复合体可以破坏胞吐途径,从而抑制VPS51的功能。 | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
Golgicide A 是高尔基体 BFA 抗性因子 1(GBF1)的特异性抑制剂,而 GBF1 是 ARF GTPase 的 GEF。通过抑制 GBF1,Golgicide A 可以阻碍来自高尔基体的囊泡运输,从而导致 VPS51 的功能抑制。 | ||||||
Ondansetron | 99614-02-5 | sc-201127 sc-201127A | 10 mg 50 mg | $80.00 $326.00 | 1 | |
血清素拮抗剂,可能会间接影响血清素信号通路,从而影响 Olr1513。 | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
钙通道阻滞剂,可能间接改变钙依赖性信号传导,影响 Olr1513。 | ||||||
Pitstop 2 | 1419093-54-1 | sc-507418 | 10 mg | $360.00 | ||
Pitstop 2通过阻断clathrin和适配蛋白之间的相互作用来抑制clathrin介导的内吞作用。由于VPS51参与与内吞作用相关的运输,因此抑制clathrin介导的进程会导致VPS51的功能抑制。 |